Medtronic, the global leader in healthcare technology, today announced the VenaSeal Spectrum Program primary endpoints and 30-day modified Aberdeen Varicose Vein Questionnaire (AVVQ) results on the use of the VenaSeal™ closure system compared to surgical stripping (SS) and endothermal ablation (ETA) for the treatment of superficial venous disease. The results, which were presented today at Charing Cross International Symposium as a podium first presentation, also include safety and anatomic [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Disclaimer
Medtronic plc published this content on
24 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
24 April 2024 15:13:40 UTC.